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ABSTRACT	
Purpose		
To	evaluate	the	rate	and	identify	risk	factors	for	high-risk	histopathology	(HRH)	features	in	
Group	D	retinoblastoma	eyes	enucleated	as	primary	or	secondary	treatment.		
Design	
Retrospective	analysis.		
Participants	
Sixty	four	enucleated	Group	D	eyes	(62	patients),	of	which	40	(40	patients)	were	primary	
and	24	(22	patients)	secondary	to	other	treatments.		
Methods		
Clinicopathologic	correlation	of	consecutive	group	D	eyes	enucleated	from	2002–2014.	HRH	
features	were	defined	as	presence	of	anterior	chamber	seeds,	iris	infiltration,	ciliary	
body/muscle	infiltration,	massive	(≥3mm)	choroidal	invasion,	retrolaminar	optic	nerve	
invasion,	or	combined	non-massive	choroidal	and	prelaminar/laminar	optic	nerve	invasion.		
Main	Outcome	Measures	
HRH	features,	metastasis	and	death.		
Results		
Of	the	64	Group	D	eyes,	37	(58%)	were	classified	as	cT2bN0M0H0,	24	(38%)	as	
cT2bN0M0H1	and	3	(5%)	as	cT2aN0M0H1,	according	to	the	8th	edition	cTNMH	
Retinoblastoma	Staging.	HRH	features	were	detected	in	10	(16%)	eyes	in	the	entire	cohort;	
in	5	(13%)	of	the	primary	(pT3aNxM0	(n=2)	and	pT3bNxM0	(n=3);	8th	edition	pTNM)	and	5	
(21%)	of	the	secondary	(pT2bNxM0	(n=2),	pT3aNxM0	(n=2)	and	pT3cNxM0	(n=1))	
enucleated	groups.	Absence	of	vitreous	seeds	at	presentation	was	the	only	predictive	factor	
found	for	HRH	features	in	the	primary	enucleation	group	(P=0.042),	whereas	none	were	
found	in	the	secondary	group	(P≥0.179).	Anterior	structures	invasion	(anterior	chamber,	iris,	
ciliary	body/muscle)	was	detected	significantly	more	after	secondary	enucleation	(P=0.048).	
All	patients	with	HRH	features	were	treated	with	adjuvant	chemotherapy	and	no	metastases	
were	recorded	in	a	median	follow-up	time	of	73.2	months	(mean:	71.5,	range:	13.7-153.0).		
Conclusion		
The	choice	of	primary	treatment	for	group	D	retinoblastoma	should	be	carefully	weighed,	
as,	according	to	this	study,	13%	of	eyes	harbor	HRH	features	at	presentation,	with	absence	
of	vitreous	seeds	being	a	potential	risk	factor.	It	is	of	special	importance	in	Group	D	eyes	
being	considered	for	non-systemic	treatment,	such	as	primary	intra-ophthalmic	artery	
chemotherapy.	Secondary	enucleated	Group	D	eyes	with	HRH	features	more	commonly	
involved	anterior	structures,	warranting	meticulous	clinical	and	histological	examinations	for	
this	subset	of	patients.		
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INTRODUCTION	
The	International	Intraocular	Retinoblastoma	Classification	(IIRC)1	was	introduced	in	2005,	
in	an	era	in	which	systemic	chemotherapy	has	become	the	main	treatment	for	intraocular	
retinoblastoma,2–5	replacing		the	Reese-Ellsworth	(R-E)	classification.6	The	IIRC	predicted	
chemotherapy	success,	with	≥90%	salvage	rate	for	groups	A-C	eyes	and	47%	salvage	rate	for	
D	eyes.7	Group	E	eyes	are	usually	enucleated,	due	to	irreversible	ocular	damage,	but	also	
due	to	the	higher	chance	of	adverse	histology.8–12	Such	high	risk	histopathological	(HRH)	
features,	as	tumour	in	the	anterior	chamber,	uveal	tract	or	optic	nerve,	are	harbingers	for	
metastatic	spread,	and	therefore	warrant	adjuvant	systemic	chemotherapy	to	reduce	the	
risk	of	death.13		
The	management	of	group	D	eyes	then	raises	a	dilemma:	that	some	eyes	undergoing	an	
attempt	at	conservative	therapy	may	actually	have	HRH,	posing	the	risk	of	metastatic	
disease.	A	shift	toward	salvage	therapy	for	group	D	eyes	has	occurred	by	use	of	systemic	
chemotherapy	and	lately	by	means	of	intra-ophthalmic	artery	chemotherapy	(IAC).14	The	
latter	has	been	the	subject	of	debate	regarding	systemic	spread.15	It	has	a	high	eye	salvage	
rate,16	but	with	selectivity	to	the	eye	there	may	be	a	potential	risk	of	developing	distant	
metastatic	disease.15	If	such	eyes	are	treated	with	systemic	chemotherapy,	then	not	only	is	
intraocular	disease	successfully	managed,	but	HRH	features	and	distant	disease	treated	at	
the	same	time.	Many	centers	have	favored	systemic	chemotherapy	for	Group	D	eyes	for	this	
reason,	as	first	line	globe	retention	therapy.		
Most	reports	of	HRH	in	the	literature	relate	to	group	E	eyes13,17	or	a	heterogeneous	mix	of	
groups	D	and	E.	8–12	In	these	studies,	analysis	of	clinical	features	predicting	HRH	are	not	
directly	applicable	to	a	physician	trying	to	decide	on	systemic	chemotherapy	versus	IAC	or	
even	enucleation	for	a	group	D	eye.	In	the	current	study	we	aimed	to	understand	better	the	
clinicopathologic	correlation	between	HRH	and	clinical	factors	in	a	large	number	of	group	D	
eyes.	By	analyzing	eyes	undergoing	primary	enucleation	and	secondary	enucleation,	where	
conservative	therapy	had	been	performed,	we	aimed	to	understand	the	clinical	factors	that	
might	predict	a	low	chance	of	HRH	that	might	lead	us	to	consider	IAC	as	a	first	line	
conservative	treatment.		
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METHODS	
This	was	a	retrospective	chart	review	of	all	IIRC	(Children’s	Hospital	Los	Angeles	version)1	
group	D	cases	from	10/04/2002	to	17/12/2014	that	were	managed	at	the	London	
Retinoblastoma	Service	by	means	of	primary	enucleation,	or	initially	with	systemic	
chemotherapy,	followed	by	adjuvant	and	salvage	treatment,	but	eventually	enucleated.	
During	the	study	period,	all	children	were	examined	and	managed	by	3	retinoblastoma	
specialists	and	histopathological	evaluation	of	eyes	that	underwent	primary	or	secondary	
enucleation	was	performed	by	2	specialist	pathologists.	An	ethical	approval	to	carry	out	this	
study	was	granted	by	the	Barts	Health	Trust	institutional	review	board	(number	6622).		
Clinical	data	retrieved	from	medical	charts	included:	age	of	presentation,	disease	laterality,	
family	history	of	retinoblastoma,	clinical	features	at	presentation,	genetic	analysis	results,	
type	of	primary,	adjuvant	and	salvage	treatments,	detailed	clinical	data	throughout	follow-
up,	development	of	distant	metastatic	spread	and	death.	In	addition,	all	imaging	scans	
performed	at	presentation	and	during	follow-up	were	reviewed	and	analyzed.		
Histopathology	
For	patients	that	underwent	primary	or	secondary	enucleation,	after	harvest	of	tumour	
tissue	for	genetic	analysis,	eyes	were	fixed	in	neutral	buffered	formalin	and	processed	for	
light	microscopy	with	sections	stained	with	hematoxylin-eosin.	Microscopic	sections	
included	the	optic	nerve	and	all	ocular	structures	at	multiple	section	levels	of	mid-globe	and	
both	calottes,	and	a	transverse	section	from	the	surgical	margin	of	optic	nerve.		
The	histopathology	reports	of	all	patients	that	underwent	enucleation	(primary	and	
secondary)	were	reviewed	and	analyzed.	In	cases	in	which	HRH	features	were	detected,	the	
histopathology	slides	were	pulled-out	and	re-analyzed.	HRH	features	were	defined	as	the	
presence	of	anterior	chamber	seeding,	iris	infiltration,	ciliary	muscle/body	infiltration,	
massive	(≥3	mm)	choroidal	invasion,	retrolaminar	optic	nerve	invasion,	invasion	of	optic	
nerve	surgical	margin,	combined	non-massive	choroidal	and	prelaminar/laminar	optic	nerve	
invasion,	or	scleral/extrascleral	infiltration.9		
	
TNM	classification	
After	including	all	IIRC	group	D	eyes	and	retrieval	of	data,	eyes	were	classified	according	to	
the	8th	edition	AJCC/UICC	clinical	staging	system	(8th	edition	cTNMH).18	In	addition,	
enucleated	high-risk	retinoblastoma	eyes	were	also	classified	according	to	the	8th	edition	
AJCC/UICC	pathological	staging	system	(8th	editions	pTNM).18			
 
Statistical	Analysis	
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All	calculations	were	performed	using	Microsoft	Excel	2013	software	(Microsoft	
Corporation,	Redmond,	WA)	and	SPSS	software	version	17.0	(SPSS,	Inc.,	Chicago,	IL).	Risk	
factors	to	develop	HRH	features	in	primarily	and	secondarily	enucleated	eyes	were	
calculated	using	Fisher's	Exact	Test	and	t-Test,	for	categorical	and	continuous	variables,	
respectively.	Comparison	of	HRH	features	between	primarily	and	secondarily	enucleated	
eyes	was	performed	using	Fisher's	Exact	Test.	An	alpha	level	of	0.05	and	two-tailed	p-values	
were	used	to	determine	statistical	significance	and	an	a	priori	decision	was	made	that	a	
multiple	comparison	correction	would	not	be	used.		
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RESULTS	
During	the	study	period,	104	group	D	eyes	(92	patients)	were	managed	at	the	London	
Retinoblastoma	Service,	40	(38%,	40	patients	(43%))	of	which	underwent	primary	
enucleation	and	64	(62%,	52	(57%)	patients))	were	treated	initially	with	systemic	
chemotherapy.	Of	the	latter	group,	24	(38%,	22	patients	(42%))	eyes	underwent	secondary	
enucleation,	and	these	together	with	the	40	primary	enucleated	eyes	comprise	the	study	
cohort.	Hence	there	were	64	Group	D	eyes	in	this	study.		
Analyzing	the	whole	study	cohort,	there	were	36	(58%)	males	and	26	(42%)	females,	19	
(30%)	presented	with	bilateral	disease,	22	(35%)	had	positive	RB1	mutation,	5	(22%)	of	
which	also	had	positive	family	history	of	retinoblastoma.	The	median	age	of	presentation	
was	21.0	months	(mean:	24.9,	range:	0.6-144.0)	and	most	common	presenting	sign	was	
leucocoria	(45	(72%)	patients).	Of	the	bilateral	cases,	the	fellow	eye	was	IIRC	group	A	in	4	
cases,	B	in	5,	C	in	2,	D	in	5	and	E	in	3.	In	terms	of	clinical	examination	at	presentation,	6	(9%)	
eyes	presented	with	multifocal	disease,	the	retina	was	detached	in	62	(97%)	eyes,	in	32	
(50%)	of	which	a	total	detachment	was	present,	predominantly	endophytic	retinoblastoma	
growth	pattern	was	present	in	36	(56%)	eyes	and	exophytic	in	28	(44%),	the	optic	disc	was	
obscured	in	58	(91%)	eyes,	a	foveal	tumour	was	present	in	48	(75%)	eyes,	subretinal	seeds	
in	22	(34%)	eyes	and	vitreous	seeds	in	29	(45%)	eyes.	In	terms	of	the	8th	edition	cTNMH,	
there	were	37	(58%)	eyes	classified	as	cT2bN0M0H0,	24	(38%)	as	cT2bN0M0H1	and	3	(5%)	
as	cT2aN0M0H1.		The	demographic,	clinical	variables,	genetic	analysis	and	8th	edition	
cTNMH	classification	subdivision	of	primary	versus	secondary	enucleated	D	eyes	is	shown	in	
Supplemental	Digital	Table	1.		
	
HRH	features	were	detected	in	10	(16%)	eyes	in	the	entire	cohort	of	64	eyes.	Of	the	40	eyes	
that	underwent	primary	enucleation,	HRH	features	were	detected	in	5	(13%).	Table	1	
summarizes	the	clinical	features	of	these	5	eyes	as	compared	to	the	35	(87.5%)	in	which	no	
HRH	features	were	found.	The	only	significant	predictor	for	HRH	features	was	the	absence	
of	vitreous	seeds	at	presentation	(P=0.042).			
	
In	the	secondary	enucleation	group,	the	standard	protocol	of	6	cycles	of	intravenous	
vincristine,	etoposide	and	carboplatin	(VEC)	was	used	in	all	patients	treated	with	primary	
systemic	chemotherapy.	Additional	adjuvant	treatments	in	this	cohort	included	diode	laser	
and/or	cryotherapy	(11	(46%)	eyes),	plaque	brachytherapy	(5	(21%)	eyes),	EBRT	(5	(21%)	
eyes),	IAC	(11	(46%)	eyes),	intra-vitreous	chemotherapy	(4	(17%)	eyes)	and	second	line	
systemic	chemotherapy	(2	(8%)	eyes).	In	5	(21%)	of	the	secondary	enucleated	eyes	HRH	
features	were	detected.	Indications	for	secondary	enucleation	in	these	cases	were	
progression	of	vitreous	disease	prior	to	the	introduction	of	intra-vitreous	chemotherapy	in	2	
cases	(despite	EBRT	in	both),	widespread	vitreous	base	relapse	combined	with	diffuse	
subretinal	hemorrhage	in	1	case	and	tumour	in	the	anterior	chamber	in	2	cases	(Figure	1).	
Table	2	summarizes	the	clinical	features	and	management	course	of	these	5	eyes	as	
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compared	to	the	19	(79%)	in	which	no	HRH	features	were	found.	None	of	the	variables	were	
found	to	be	significant	predictors	to	develop	HRH	features	(P≥0.179).		
	
The	detailed	HRH	features	found	in	the	5	primarily	versus	5	secondarily	enucleated	eyes,	
including	the	8th	pTNM	classification,	are	shown	in	Table	3.	Optic	nerve	and/or	choroidal	
tumour	invasion	(Figure	2)	was	detected	in	5	(100%)	eyes	that	underwent	primary	
enucleation	as	compared	to	3	(60%)	that	underwent	secondary	enucleation	(p=0.444).	
Superficial	scleral	invasion	was	detected	in	one	secondary	enucleated	case.	Regarding	
anterior	structures	tumour	involvement	(anterior	chamber,	iris,	ciliary	body	and/or	muscle),	
these	were	detected	in	none	(0%)	of	the	primarily	enucleated	eyes	as	compared	to	4	(80%)	
eyes	that	underwent	secondary	enucleation	(P=0.048).		
	
The	5	patients	diagnosed	with	HRH	features	following	primary	enucleation	were	further	
treated	with	4	cycles	of	adjuvant	VEC,	and	5	patients	diagnosed	with	HRH	following	
secondary	enucleation	were	treated	with	4	cycles	of	ifosfamide,	vincristine	and	doxorubicin	
(IVAd;	n=3),	topotecan,	vincristine	and	doxorubicin	(TVD;	n=1)	or	thiotepa	(n=1),	depending	
on	previous	treatments	and	at	the	discretion	of	the	managing	medical	oncologist.	The	whole	
cohort	(N=64	eyes)	was	followed-up	for	a	median	time	of	73.2	months	(mean:	71.5,	range:	
13.7-153.0)	and	the	10	patients	with	HRH	features	for	78.6	months	(mean:	79.7,	range:	
19.4-162.6).	During	this	time,	none	of	the	patients	has	developed	metastatic	disease	or	
died.		
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DISCUSSION	
A	choice	of	many	treatments	is	available	to	the	retinoblastoma	specialist	and	several	factors	
play	a	role	in	determining	the	opening	strategy	in	treating	this	cancer.	Much	emphasis	has	
been	placed	on	conserving	eyes	that	previously	were	enucleated	as	experience	and	
technological	knowledge	has	advanced,	first	with	systemic	chemotherapy,	then	IAC.	The	
latter	is	an	attractive	option,	with	great	success	of	globe	retention,	even	in	Group	D	eyes.16	
However,	there	is	controversy	regarding	the	possibility	of	metastasis	and	ultimately	
whether	there	is	a	risk	of	mortality.15	The	predictor	of	metastasis	is	tumour	invasion	to	the	
choroid	(>	3mm),	optic	nerve	or	anterior	chamber,	as	these	may	act	as	portals	outside	the	
eye.	While	systemic	chemotherapy	will	simultaneously	treat	these	high-risk	histopathology	
features	and	micrometastatic	disease	that	has	already	left	the	eye,	IAC	will	only	treat	the	
eye.	The	dilemma	this	poses	is	hardest	in	group	D	eyes,	where	the	inclination	is	for	
conservative	localized	therapy	with	IAC,	but	the	fear	is	risk	of	metastasis,	as	reported	by	
Abramson	et	al.	in	6%.16	In	this	study	we	tried	to	better	understand	which	clinical	features	
would	be	able	to	predict	HRH	in	group	D	eyes,	and	hence	aid	selection	for	IAC.			
	
In	the	present	study	HRH	features	were	detected	in	10	(16%)	eyes	in	the	entire	cohort.	In	
the	primary	enucleation	group	13%	harbored	high-risk	histopathological	features	for	
systemic	spread.	All	these	patients	were	thereafter	treated	with	4	cycles	of	adjuvant	
intravenous	chemotherapy	and	none	has	developed	metastases	at	a	median	follow-up	of	
78.9	months.	The	rate	of	HRH	features	in	primary	enucleated	D	eyes	found	in	the	literature	
ranges	from	13–33%,	depending	on	the	series	and	treating	center	(Table	4).8–12	In	4	(80%)	of	
these	studies,	rates	ranged	from	13-17%,8–10,12	in	keeping	with	our	findings.	All	studies	
included	both	D	and	E	eyes,	in	the	latter	of	which	HRH	features	were	found	to	be	more	
prevalent.	In	3	(60%)	of	the	studies	in	which	clinical	features	to	predict	HRH	features	were	
investigated,	IIRC	group	E,	or	typical	features	of	this	group	(e.g.	secondary	glaucoma),	were	
found	to	be	significant.	Hitherto	HRH	in	group	D	eyes	has	not	been	assessed	as	a	standalone	
group,	so	group	E	clinical	features	are	not	directly	relevant	when	faced	with	deciding	on	
treatment	for	a	group	D	eye.		
		
Our	findings	indicate	that	absence	of	vitreous	seeds	at	presentation	was	the	only	significant	
predictive	factor	for	HRH	features	in	primary	Group	D	enucleated	eyes.	No	support	for	these	
findings	was	found	in	the	literature.	It	could	be	hypothesized	that	the	action	of	seeding	into	
the	vitreous	may	be	associated	with	a	decompressing	effect	on	the	main	tumour	on	the	
choroid	and/or	optic	disc.	It	could	also	be	associated	with	growth	pattern.	However,	our	
analysis	indicated	that	endophytic	versus	exophytic	pattern	was	a	non-significant	variable	
for	HRH.	Conversely,	Palazzi	et	al.19	found	that	primary	enucleated	eyes	with	exophytic	
retinoblastoma	had	significantly	more	choroidal	invasion	compared	to	endophytic	
retinoblastoma,	though	their	study	was	conducted	in	the	era	of	EBRT	and	enucleation,	
before	the	widespread	introduction	of	chemotherapy.	In	our	study,	subretinal	seeds	were	
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present	in	the	majority	of	both	groups	of	primary	enucleated	eyes,	with	or	without	HRH	
features,	and	were	not	found	to	be	a	significant	predictor	for	HRH.	
	
In	21%	of	secondary	enucleated	eyes	HRH	features	were	detected.	The	rate	of	HRH	features	
in	this	group	are	in	keeping	with	those	previously	reported	by	Brennan	et	al.	(HRH	features	
found	in	21%	of	groups	B-D	and	18%	of	group	D	secondarily	enucleated	eyes).10	No	clinical	
predictors	to	develop	HRH	features	were	found	in	the	secondary	enucleation	group	of	eyes.	
Of	note,	all	patients	that	underwent	secondary	enucleation	had	previously	received	
systemic	chemotherapy,	potentially	masking	the	extent	of	HRH	features	in	this	sub-
population.20	However,	in	contrast	to	being	neoadjuvant	therapy	given	immediately	prior	to	
enucleation,	in	most	cases	in	the	present	study,	enucleation	was	performed	a	long	period	
after	primary	systemic	chemotherapy	was	given,	so	presumably	it	had	little	or	no	masking	
effect.		
	
The	involvement	of	anterior	structures	by	retinoblastoma,	a	HRH	feature,	occurred	more	
commonly	in	the	secondary	enucleation	group.	Brennan	et	al.	also	found	cases	of	anterior	
involvement	after	secondary	enucleation,	but	in	a	cohort	that	included	a	range	of	IIRC	
groups,	precluding	a	direct	comparison	to	our	results.	In	a	previous	report,	we	found	
anterior	invasion	on	histopathology	after	failed	IAC		in	67%	of	IIRC	groups	B-D	secondary	
enucleated	eyes.21	In	the	present	study	concentrating	solely	on	group	D	eyes,	previous	IAC	
was	not	a	significant	factor	for	HRH	features,	nor	for	anterior	structures	involvement.	
Abramson	and	Gombos,	in	a	study	on	the	topography	of	retinoblastoma	lesions	in	bilateral	
cases,22	found	that	anterior	tumours	(i.e.	anterior	to	equator)	tended	to	develop	at	a	later	
age	or	later	in	the	course	of	disease,	compared	to	posterior	pole	tumours.	This	idea	
supports	our	results,	that	more	advanced	or	refractory	retinoblastoma	tumours	propagate	
anteriorly.	Anterior	involvement	following	secondary	enucleation	was	found	in	4	eyes	on	
histopathology,	but	detected	clinically	only	in	2,	in	which	tumour	seeds	were	clearly	seen	in	
the	anterior	chamber.	Retinoblastoma	infiltrating	into	the	ciliary	body	was	more	easily	
missed	on	clinical	examination,	further	highlighting	the	need	for	a	meticulous	
histopathology	examination	of	all	intraocular	sites	in	enucleated	retinoblastoma	eyes.		
	
Limitations	of	the	study	include	its	retrospective	design.	Nevertheless,	we	were	able	to	
retrieve	detailed	data	from	medical	charts	and	imaging	devices	in	a	relatively	large	group	D	
retinoblastoma	cohort	and	to	reassess	histopathology	slides	of	patients	with	HRH	features.	
Some	ambiguity	exists	in	the	clinical	features	in	a	group	D	eye	such	as	tumour	focality	
(unifocal	versus	multifocal),	presence	of	retinal	seeds,	especially	when	a	large	retinal	
detachment	is	present,	and	tumour	growth	type	(endophytic	versus	exophytic).	Review	of	
sequential	imaging	was	found	to	be	useful.	Detection	of	vitreous	seeds	on	clinical	
examination,	in	contrast,	is	an	easier	and	presumably	more	accurate	undertaking.	
Interestingly,	this	was	found	to	be	the	only	significant	variable	to	predict	HRH	features.	In	
this	regard,	with	increased	statistical	testing,	the	family-wise	error	rate	in	general	
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increases.23	However,	given	the	small	sample	size,	which	works	against	the	power	of	the	
statistical	comparisons,	we	continue	to	believe	that	any	statistically	significant	finding,	even	
in	the	setting	of	an	uncorrected	p-value,	could	be	clinically	relevant	and	should	be	
considered	during	future	retinoblastoma	research.		
	
In	summary,	in	this	study,	high-risk	histopathology	features	were	found	in	13%	and	21%	of	
primary	and	secondary	enucleated	group	D	retinoblastoma	eyes,	respectively.	All	patients	
were	treated	with	adjuvant	systemic	chemotherapy	and	no	cases	of	distant	metastases	or	
deaths	were	recorded.	Vitreous	seeds	at	presentation	were	found	significantly	more	in	
patients	with	no	HRH	features,	potentially	serving	as	a	clinical	sign	to	be	taken	into	account	
when	deciding	on	the	mode	of	primary	treatment.	It	is	of	additional	importance	in	case	eye-
selective	intra-ophthalmic	artery	chemotherapy	is	to	be	considered,	as	these	patients	may	
not	be	systemically	protected.	Anterior	structures	involvement	was	found	significantly	more	
after	initial	treatment	with	conservative	chemotherapy	compared	to	primary	enucleation,	in	
some	cases	only	subclinically,	proven	on	histopathology	alone.	Meticulous	clinical	
examination	is	warranted	as	well	as	careful	histopathology	evaluation	after	a	group	D	
retinoblastoma	eye	is	removed.		
	 	
Risk	Group	D	Retinoblastoma-High	/et	al.		Fabian	
	
11	
	
Acknowledgment		
We	gratefully	acknowledge	the	contribution	of	the	late	Dr	Judith	Kingston,	Consultant	
Paediatric	Oncologist,	for	the	introduction	of	systemic	chemotherapy	for	intraocular	
retinoblastoma,	including	for	the	patients	reported	herein.	We	also	thank	our	specialist	
retinoblastoma	nurses,	Maxine	Fraser,	Laura	Rouse	and	Charlotte	Clifton	for	assistance	with	
this	study.		
	
	
	 	
Risk	Group	D	Retinoblastoma-High	/et	al.		Fabian	
	
12	
	
REFERENCES	
1.	Linn	Murphree	A.	Intraocular	retinoblastoma:	the	case	for	a	new	group	classification.	
Ophthalmol	Clin	North	Am.	2005;18:41–53.		
2.	Gallie	BL,	Budning	A,	DeBoer	G,	et	al.	Chemotherapy	with	focal	therapy	can	cure	
intraocular	retinoblastoma	without	radiotherapy.	Arch	Ophthalmol	(Chicago,	Ill		1960).	
1996;114:1321–8.		
3.	Kingston	JE,	Hungerford	JL,	Madreperla	SA,	Plowman	PN.	Results	of	combined	
chemotherapy	and	radiotherapy	for	advanced	intraocular	retinoblastoma.	Arch	Ophthalmol	
(Chicago,	Ill		1960).	1996;114:1339–43.		
4.	Murphree	AL,	Villablanca	JG,	Deegan	WF,	et	al.	Chemotherapy	plus	local	treatment	in	the	
management	of	intraocular	retinoblastoma.	Arch	Ophthalmol	(Chicago,	Ill		1960).	
1996;114:1348–56.		
5.	Shields	CL,	De	Potter	P,	Himelstein	BP,	et	al.	Chemoreduction	in	the	initial	management	of	
intraocular	retinoblastoma.	Arch	Ophthalmol	(Chicago,	Ill		1960).	1996;114:1330–8.		
6.	REESE	AB,	ELLSWORTH	RM.	The	evaluation	and	current	concept	of	retinoblastoma	
therapy.	Trans	Am	Acad	Ophthalmol	Otolaryngol.	1963;67:164–72.		
7.	Shields	CL,	Mashayekhi	A,	Au	AK,	et	al.	The	International	Classification	of	Retinoblastoma	
predicts	chemoreduction	success.	Ophthalmology.	2006;113:2276–80.		
8.	Wilson	MW,	Qaddoumi	I,	Billups	C,	et	al.	A	clinicopathological	correlation	of	67	eyes	
primarily	enucleated	for	advanced	intraocular	retinoblastoma.	Br	J	Ophthalmol.	
2011;95:553–8.		
9.	Kaliki	S,	Srinivasan	V,	Gupta	A,	et	al.	Clinical	Features	Predictive	of	High-Risk	
Retinoblastoma	in	403	Asian	Indian	Patients	A	Case-Control	Study.	Ophthalmology.	
2015;122:1165–1172.		
10.	Brennan	RC,	Qaddoumi	I,	Billups	CA,	et	al.	Comparison	of	high-risk	histopathological	
features	in	eyes	with	primary	or	secondary	enucleation	for	retinoblastoma.	Br	J	Ophthalmol.	
2015;99:1366–71.		
11.	Yousef	YA,	Al-Hussaini	M,	Mehyar	M,	et	al.	PREDICTIVE	VALUE	OF	TNM	CLASSIFICATION,	
INTERNATIONAL	CLASSIFICATION,	AND	REESE-ELLSWORTH	STAGING	OF	RETINOBLASTOMA	
FOR	THE	LIKELIHOOD	OF	HIGH-RISK	PATHOLOGIC	FEATURES.	Retina.	2015;35:1883–9.		
12.	Kaliki	S,	Shields	CL,	Rojanaporn	D,	et	al.	High-risk	retinoblastoma	based	on	international	
classification	of	retinoblastoma:	analysis	of	519	enucleated	eyes.	Ophthalmology.	
2013;120:997–1003.		
13.	Kaliki	S,	Shields	CL,	Shah	SU,	et	al.	Postenucleation	adjuvant	chemotherapy	with	
vincristine,	etoposide,	and	carboplatin	for	the	treatment	of	high-risk	retinoblastoma.	Arch	
Ophthalmol	(Chicago,	Ill		1960).	2011;129:1422–7.		
14.	Abramson	DH,	Shields	CL,	Munier	FL,	Chantada	GL.	Treatment	of	Retinoblastoma	in	
2015:	Agreement	and	Disagreement.	JAMA	Ophthalmol.	2015:1–7.		
15.	Yousef	YA,	Soliman	SE,	Astudillo	PPP,	et	al.	Intra-arterial	Chemotherapy	for	
Risk	Group	D	Retinoblastoma-High	/et	al.		Fabian	
	
13	
	
Retinoblastoma:	A	Systematic	Review.	JAMA	Ophthalmol.	2016	[Epub	ahead	of	print].		
16.	Abramson	DH,	Daniels	AB,	Marr	BP,	et	al.	Intra-Arterial	Chemotherapy	(Ophthalmic	
Artery	Chemosurgery)	for	Group	D	Retinoblastoma.	PLoS	One.	2016;11:e0146582.		
17.	Chawla	B,	Sharma	S,	Sen	S,	et	al.	Correlation	between	clinical	features,	magnetic	
resonance	imaging,	and	histopathologic	findings	in	retinoblastoma:	A	prospective	study.	
Ophthalmology.	2012;119:850–856.		
18.	Mallipatna	AC,	Gallie	BL,	Chévez-Barrios	P		et	al.	Retinoblastoma.	In:	Amin	MB,	Edge	SB,	
Greene	FL,	et	al.,	eds.	AJCC	Cancer	Staging	Manual.	8th	ed.	New	York:	Springer;	2017.	
19.	Palazzi	M,	Abramson	DH,	Ellsworth	RM.	Endophytic	vs	exophytic	unilateral	
retinoblastoma:	is	there	any	real	difference?	J	Pediatr	Ophthalmol	Strabismus.	1990;27:255–
8.		
20.	Zhao	J,	Dimaras	H,	Massey	C,	et	al.	Pre-enucleation	chemotherapy	for	eyes	severely	
affected	by	retinoblastoma	masks	risk	of	tumor	extension	and	increases	death	from	
metastasis.	J	Clin	Oncol.	2011;29:845-51.		
21.	Pavlidou	E,	Burris	C,	Thaung	C,	et	al.	Anterior	Segment	Seeding	in	Eyes	With	
Retinoblastoma	Failing	to	Respond	to	Intraophthalmic	Artery	Chemotherapy.	JAMA	
Ophthalmol.	2015;133:1455–8.		
22.	Abramson	DH,	Gombos	DS.	The	topography	of	bilateral	retinoblastoma	lesions.	Retina.	
1996;16:232–9.		
23.	Stacey	AW,	Pouly	S,	Czyz	CN.	An	analysis	of	the	use	of	multiple	comparison	corrections	
in	ophthalmology	research.	Invest	Ophthalmol	Vis	Sci.	2012;53:1830-4.		
	 	
Risk	Group	D	Retinoblastoma-High	/et	al.		Fabian	
	
14	
	
FIGURE	LEGEND	
Figure	1	–	(A)	Color	photograph	(RetCam,	City,	USA)	showing	retinoblastoma	tumour	cells	in	
the	anterior	chamber	(arrow)	and	(B)	histopathology	of	the	same	eye	after	secondary	
enucleation	showing	viable	tumour	cells	attached	to	the	iris	and	extending	into	the	drainage	
angle	and	cornea.		
Figure	2	–	Histopathology	after	primary	enucleation	showing	(A)	choroidal	and	(B)	retro-
laminar	invasion.		
	
Figure	1A	
	
Figure	1B	
	
Figure	2A	
	
Figure	2B	
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Table	1.	Clinical	features	of	40	(40	patients)	primary	enucleated	group	D	eyes:	high-risk	
histopathology	(HRH)	features	(n=5)	versus	no	HRH	features	(n=35).		
Parameter	 HRH	features	(N=5)		 No	HRH	features	(N=35)	 Significance	
Gender		
										Male		
										Female	
	
2	(40%)	
3	(60%)	
	
20	(57%)	
15	(43%)	
P=0.642	
Uni/bilateral	retinoblastoma	
										Unilateral		
										Bilateral		
	
4	(80%)	
1	(20%)	
	
33	(94%)	
2	(6%)	
P=0.338	
Age	of	diagnosis	(months)	
										Median	(mean,	range)	
	
24.0	(24.0,	1.0-60.0)	
	
22.0	(21.2,	4.0-36.0)	
P=0.683	
Presenting	signs		
										Leucocoria	
										Strabismus	
										Leucocoria	and	strabismus	
	
4	(80%)	
1	(20%)	
0	(0%)	
	
28	(80%)	
6	(17%)	
1	(3%)	
P=0.922	
RB1	Blood	mutation	
										Negative	
										Positive	
	
4	(80%)	
1	(20%)	
	
28	(80%)	
7	(20%)	
P=1.000	
Laterality	
										RE	
										LE	
	
3	(60%)	
2	(40%)	
	
18	(51%)	
17	(49%)	
P=1.000	
Tumour	focality	
										Unifocal	
										Multifocal	
	
5	(100%)	
0	(0%)	
	
34	(97%)	
1	(3%)	
P=1.000	
Retinoblastoma	growth	pattern	
										Endophytic	
										Exophytic	
	
1	(20%)	
4	(80%)	
	
21	(60%)	
14	(40%)	
P=0.155	
Optic	disc	obscured		
										Not	obscured	
										Obscured	
	
0	(0%)	
5	(100%)	
	
2	(6%)	
33	(94%)	
P=1.000	
Fovea	involvement		
										Not	involved	
	
0	(0%)	
	
2	(6%)	
P=0.490	
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										Sub-foveal	fluid	
										Foveal	tumour	
0	(0%)	
5	(100%)	
6	(17%)	
27	(77%)	
Retinoblastoma	seeds		
										No	seeds	
										Sub-retinal	
										Vitreous	
	
0	(0%)	
4	(80%)	
1	(20%)	
	
0	(0%)	
21	(60%)	
25	(71%)	
	
P=1.000	
P=0.633	
P=0.042	
	
Table	2.	Clinical	features	at	presentation	and	initial	management	of	24	(22	patients)	group	D	eyes	that	
underwent	secondary	enucleation:	high-risk	histopathological	(HRH)	features	(n=5)	versus	no	HRH	
features	(n=19).		
Parameter	 HRH	Features	(N=5)		 No	HRH	Features	(N=19)	 Significance	
Gender		
										Male		
										Female	
	
3	(60%)	
2	(40%)	
	
14	(74%)	
5	(26%)	
P=0.608	
Uni/bilateral	retinoblastoma	
										Unilateral		
										Bilateral		
	
2	(40%)	
3	(60%)	
	
4	(21%)	
15	(79%)	
P=0.568	
Age	of	diagnosis	(months)	
										Median	(mean,	range)	
	
20.0	(42.6,	5.0-144.0)	
	
10.0	(23.0,	0.6-108.0)	
P=0.303	
RB1	Blood	mutation	
										Negative	
										Positive	
	
2	(40%)	
3	(60%)	
	
4	(21%)	
15	(79%)	
P=0.568	
Laterality	
										RE	
										LE	
	
4	(80%)	
1	(20%)	
	
14	(74%)	
5	(26%)	
P=1.000	
Tumour	focality	
										Unifocal	
										Multifocal	
	
4	(80%)	
1	(20%)	
	
15	(79%)	
4	(21%)	
P=1.000	
Retinoblastoma	growth	pattern	
										Endophytic	
										Exophytic	
	
3	(60%)	
2	(40%)	
	
11	(58%)	
8	(42%)	
P=1.000	
Optic	disc	obscured		
										Not	obscured	
										Obscured	
	
2	(40%)	
3	(60%)	
	
2	(11%)	
17	(89%)	
P=0.179	
Fovea	involvement		
										Not	involved	
										Sub-foveal	fluid	
										Foveal	tumour	
	
1	(20%)	
2	(40%)	
2	(40%)	
	
2	(11%)	
3	(16%)	
14	(74%)	
P=0.849	
Retinoblastoma	seeds		
										No	seeds	
										Sub-retinal	
										Vitreous	
	
0	(0%)	
4	(80%)	
3	(60%)	
	
3	(16%)	
13	(68%)	
6	(32%)	
	
P=1.000	
P=1.000	
P=0.326	
Adjuvant/salvage	treatments	
										Diode	laser/cryo	
										Plaque	brachytherapy	
										IAC	
	
2	(40%)	
2	(40%)	
3	(60%)	
	
9	(47%)	
3	(16%)	
8	(42%)	
	
P=1.000	
P=0.271	
P=0.630	
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										Intra-vitreous	chemotherapy	
										EBRT	
0	(0%)	
2	(40%)	
1	(5%)	
3	(16%)	
P=1.000	
P=0.271	
Time	to	enucleation	(months)	
										Median	(mean,	range)	
	
27.1	(27.0,	17.0-39.9)	
	
8.9	(22.9,	2.6-91.0)	
P=0.729	
IAC	–	intra-ophthalmic	artery	chemotherapy;	EBRT	–	external	beam	radiotherapy.		
	
Table	3.	High-risk	histopathological	(HRH)	features	in	primary	(n=5)	and	secondary	(n=5)	enucleated	group	D	eyes:	type	of	HRH	features	and	8th	AJCC	pTNM	
Retinoblastoma	staging.18	
#	 RE/LE	 High-risk	histopathological	features	 8th	ed.	pTNM	
	 	 CM/CB/iris/AC	
invasion	
ON	invasion	 Choroidal	invasion	 Scleral/	extrascleral	
invasion	
	
	 	 	 Prelaminar/	
laminar		
Retrolaminar		 Transection	 Non-massive		 Massive		 	 	
Primary	enucleation	
1	 LE	 -	 	 +	 -	 -	 -	 -	 pT3bNxM0	
2	 LE	 -	 	 +	 -	 +	 -	 -	 pT3bNxM0	
3	 RE	 -	 +	 	 -	 	 +	 -	 pT3aNxM0	
4	 RE	 -	 -	 -	 -	 	 +	 -	 pT3aNxM0	
5	 RE	 -	 	 +	 -	 +	 -	 -	 pT3bNxM0	
Secondary	enucleation	
6	 LE	 CM,	CB,	iris	&	
AC		
-	 -	 -	 -	 -	 -	 pT2bNxM0	
7	 RE	 CB	&	iris	 -	 -	 -	 -	 -	 -	 pT2bNxM0	
8	 RE	 CM,	iris	&	AC	 -	 -	 -	 	 +	 Superficial	scleral	
invasion	
pT3cNxM0	
9	 LE	 Reaches	but	
does	not	
infiltrate	CB	
-	 -	 -	 	 +	 -	 pT3aNxM0	
10	 RE	 CB	 +	 	 -	 	 +	 -	 pT3aNxM0	
CM	–	ciliary	muscle,	CB	–	ciliary	body,	AC	–	anterior	chamber,	ON	–	optic	nerve.		
Table	4.	High-risk	histopathological	(HRH)	features	in	primarily	enucleated	retinoblastoma	eyes:	comparison	to	
published	reports	in	which	group	D	eyes	were	included.		
Authors	 Year	 Number	of	eyes	(%)	 Eyes	with	HRH	features	
(%	of	IIRC	group)	
Clinical	variables	predictive	of	
HRH	features	
	 	 D	 E	 D	 E	 	
8Wilson	et	al.	 2011	 47	(70)	 20	(30)	 6	(13)	 10	(50)	 IIRC	group	E	
9Kaliki	et	al.	 2015	 50	(12)	 353	(88)	 8	(16)	 137	(39)	 prolonged	duration	of	
symptoms	of	>6	months	and	
secondary	glaucoma	
*11Yousef	et	al.	 2015	 24	(57)	 18	(43)	 8	(33)	 11	(61)	 clinical	TNM		edition	th7	igherH
stage	and	more	advanced	ICRB	
group	(i.e.,	group	E	eyes)	
**	10Brennan	et	al.	 2015	 54	(39)	 86	(61)	 8	(15)	 37	(43)	 NA	
	12Kaliki	et	al.	 2013	 87	(17)	 432	(83)	 15	(17)	 102	(24)	 NA	
Fabian	et	al.	
(present	study)	
2016	 40	(100)	 -	 5	(13)	 -	 Absence	of	vitreous	seeds	at	
presentation	
1International	Intraocular	Retinoblastoma	Classification.	–IIRC		
*	Eight	IIRC	group	C	were	also	included	in	the	study,	in	1	of	which	HRH	features	were	detected.		
**	One	IIRC	group	B	and	1	group	C	were	also	included	in	the	study,	in	addition	to	2	cases	in	which	IIRC	grouping	
was	not	available.	In	one	of	the	latter	cases,	HRH	features	were	detected.		
	
Supplemental	Digital	Table	1.		Primary	versus	secondary	enucleation	in	64	group	D	eyes:	
demographic,	clinical	variables,	genetic	analysis	and	classification	according	to	the	8th	edition	
cTNMH	Retinoblastoma	Staging.18	
Parameter	 Primary	enucleation		
N=40	patients	(%)	
N=40	eyes	(%)	
Secondary	enucleation		
N=22	patients	(%)	
N=24	eyes	(%) 
Gender	
										Male		
										Female	
	
22	(55)	
18	(45)	
	
14	(64)	
8	(36)	
Uni/bilateral	retinoblastoma	
										Unilateral	at	presentation		
										Bilateral	at	presentation	
	
37	(93)	
3	(7)	
	
6	(28)	
16	(72)	
Age	of	diagnosis	(months)	
										Median	(mean,	range)	
	
24.0	(23.7,	1.0-60.0)	
	
12.5	(8.8,	0.6-144.0)	
Family	history	of	retinoblastoma	
											Negative	(sporadic)	
											Positive	(familial)	
	
40	(100)	
0	(0)	
	
17	(77)	
5	(23)	
RB1	Blood	mutation	
										Negative	
										Positive	
	
32	(80)	
8	(20)	
	
6	(27)	
16	(73)	
Tumour	focality		
										Unifocal	
										Multifocal	
	
39	(98)	
1	(2)	
	
19	(79)	
5	(21)	
Tumour	dimensions	(mm)	
										Median	(mean,	range)	
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																				Height	
																				Base	
10.4	(10.4,	6.9-13.7)	
14.2	(14.1,	9.2-17.5)	
11.5	(10.8,	5.1-13.9)	
14.3	(13.6,	8.8-16.2)	
Quadrants	of	retinal	detachment	
										No	detachment	
										Local	
										1	
										2	
										3	
										4	
	
2	(5)	
6	(15)	
3	(8)	
3	(8)	
8	(20)	
18	(45)	
	
0	(0)	
4	(17)	
1	(4)	
3	(13)	
2	(8)	
14	(58)	
Retinoblastoma	growth	pattern	
										Endophytic	
										Exophytic	
	
22	(55)	
18	(45)	
	
14	(58)	
10	(42)	
Optic	disc	obscured	
										Not	obscured	
										Obscured	
	
2	(5)	
38	(95)	
	
4	(17)	
20	(83)	
Fovea	involvement	
										Not	involved	
										Sub-foveal	fluid	
										Foveal	tumour	
	
2	(5)	
6	(15)	
32	(80)	
	
3	(13)	
5	(21)	
16	(67)	
Retinoblastoma	seeds	
										No	seeds	
										Sub-retinal	
										Vitreous	
	
0	(0)	
15	(38)	
14	(35)	
	
3	(13)	
7	(29)	
15	(63)	
8th	edition	cTNMH	
									cT2bN0M0H0	
										cT2bN0M0H1	
										cT2aN0M0H0	
										cT2aN0M0H1	
	
32	(50%)	
8	(13%)	
0	(0%)	
0	(0%)	
	
5	(8%)	
16	(25%)	
0	(0%)	
3	(5%)	
Time	to	enucleation	(months)	
										Median	(mean,	range)	
	
0.2	(0.3,	0.2-1.4)	
	
16.2	(23.7,	2.6,	91.0)	
Total	follow-up	time	(months)	
										Median	(mean,	range)	
	
73.2	(68.8,	19.0-124.9)	
	
73.2	(76.1,	13.7-153.0)	
	
